Un premier semestre marqué par une croissance de 1%1 à taux de change constants et par l’impact significatif de la pandémie de COVID-19

    NEXT STORY
    Prospective Study Finds Potential Utility of MeMed’s Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients
    PREV STORY
    BioNTech Announces Pricing of Upsized Underwritten Offering and Terms of Rights Offering
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Retrophin and Censa Pharmaceuticals Enter into Strategic Collaboration to Advance CNSA-001 for the Treatment of Phenylketonuria (PKU)

    Retrophin obtains exclusive option to purchase Censa post proof-of-concept study Phase 2 proof-of-concept study ...

    author_avatar
    NASDAQ Market News

    In Vitro Testing of Innovation Pharmaceuticals’ Brilacidin for COVID-19 Shows Consistent Anti-SARS-CoV-2 Efficacy; Manufacturing Preparation Underway for COVID-19 Clinical Trial

    author_avatar
    NASDAQ Market News

    Editas Medicine Names Charles Albright as Chief Scientific Officer

    CAMBRIDGE, Mass., Aug. 22, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading ...

    author_avatar
    NASDAQ Market News